Massachusetts General Hospital Psychopharmacology and Neurotherapeutics

Dr. Theodore A. Stern is the Ned H. Cassem Professor of Psychiatry in the field of Psychosomatic Medicine/Consultation at Harvard Medical School (HMS), Chief Emeritus of The Avery D. Weisman, Psychiatry Consultation Service, and Director of the Thomas P. Hackett Center for Scholarship in Psychosomatic Medicine at the Massachusetts General Hospital (MGH). Dr. Stern has co-authored more than 550 peer-reviewed journal articles and book chapters, and he has edited or authored more than 60 books (including the MGH Handbook of General Hospital Psychiatry, the MGH Psychiatry Update and Board Preparation, Learning About Psychopharmacology, Facing Overweight and Obesity, Facing Pelvic Pain, Facing Memory Loss and Dementia, Facing Serious Mental Illness, and the MGH Study Guide for Psychiatry Exams). Dr. Stern is a Past-President of the Academy of Consultation-Liaison Psychiatry (ACLP) and is the Editor-in-Chief Emeritus of its journal, Psychosomatics (now called Journal of the Academy of Consultation-Liaison Psychiatry). He has won the coveted "Best Teacher Award” from the graduating residents at the MGH/McLean Hospital Psychiatric Residency Training Program, the Cynthia N. Kettyle Teaching Award from the HMS Department of Psychiatry, the MGH Department of Psychiatry's Award for Exceptional Mentorship in the Clinical Realm, a Lifetime Achievement Award from the Society of Liaison Psychiatry, and the Thomas P. Hackett Award from the ACLP (its highest honor). Dr. Maurizio Fava is Chair of the Department of Psychiatry at the Massachusetts General Hospital (MGH). Dr. Fava obtained his MD from University of Padova School of Medicine (residency in endocrinology); he completed residency training in psychiatry at the MGH. He founded and was director of the hospital's Depression Clinical and Research Program (DCRP) from 1990 to 2014. In 2007, he founded and is now Executive Director of the MGH Clinical Trials Network and Institute (CTNI), the first academic CRO specialized in planning and coordination of multi-center clinical trials in psychiatry. Under Dr. Fava's direction, the DCRP became one of the most highly regarded depression programs in the country, a model for academic programs that link, in a bi-directional fashion, clinical and research work. His prominence in the field is reflected in his role as the co-principal investigator of STAR*D, the largest research study ever conducted in the area of depression, and of the RAPID Network, the NIMH-funded series of studies of novel, rapidly acting antidepressant therapies. Dr. Fava is a world leader in the field of depression. He has authored or co-authored more than 900 original articles published in medical journals with international circulation, edited eight books, and has been successful in obtaining funding as principal or co-principal investigator from both the National Institutes of Health and other sources for a total of more than $150 million. Dr. Timothy Wilens is Chief of the Division of Child and Adolescent Psychiatry and is Co-director of the Center for Addiction Medicine at Massachusetts General Hospital (MGH). He is the MGH Trustees Chair in Addiction Medicine and Professor of Psychiatry at Harvard Medical School (HMS). Dr. Wilens earned his MD at the University of Michigan Medical School in Ann Arbor and completed his residency in child, adolescent, and adult psychiatry at the MGH. Dr. Wilens' research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders; embedded health care models; and the pharmacotherapy of ADHD across the lifespan. He has published more than 350 peer-reviewed articles concerning these and related topics. He has also co-edited more than 90 book chapters, 5 books, and 350 abstracts and presentations for national and international scientific meetings. Dr. Wilens is a distinguished fellow of the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry and serves on the board or as a scientific reviewer for more than 35 journals.